Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study - Kantarjian, H; Thomas, D; Jorgensen, J (Lancet Oncol, 2012)
et al.